Weitere Artikel dieser Ausgabe durch Wischen aufrufen
The recent withdrawal of Cox-2 Inhibitors has generated debate on the role of information in drug diffusion: can the market learn the efficacy of new drugs, or does it depend solely on manufacturer advertising and FDA updates? In this study, we use a novel data set to study the role of learning in the diffusion of three Cox-2 Inhibitors—Celebrex, Vioxx and Bextra—before the Vioxx withdrawal. Our study has two unique features: first, we observe each patient’s reported satisfaction after consuming a drug. This patient level data set, together with market level data on FDA updates, media coverage, academic articles, and pharmaceutical advertising, allows us to model individual prescription decisions. Second, we distinguish across-patient learning of a drug’s general efficacy from the within-patient learning of the match between a drug and a patient. Our results suggest that prescription choice is sensitive to many sources of information. At the beginning of 2001 and upon Bextra entry in January 2002, doctors held a strong prior belief about the efficacy of Celebrex, Vioxx, and Bextra. As a result, the learning from patient satisfaction is gradual and more concentrated on drug-patient match than on across-patient spillovers. News articles are weakly beneficial for Cox-2 drug sales, but academic articles appear to be detrimental. The impact of FDA updates is close to zero once we control for academic articles, which suggests that FDA updates follow academic articles and therefore deliver little new information to doctors. Two counterfactual experiments are carried out to quantify the influence of information on market shares.
Avorn, J., & Soumerai, S. B. (1983). Improving drug-therapy decisions through educational outreach: A randomized controlled trial of academically based ‘detailing’. New England Journal of Medicine, 308(24), 1457–1463. CrossRef
Azoulay, P. (2002). Do pharmaceutical sales respond to scientific evidence? Journal of Economics and Management Strategy, 11(4), 551–594. CrossRef
Bowman, D., Heilman, C., & Seetharaman, S. (2004). Determinants of product-use compliance behavior. Journal of Marketing Research, 41, 324–338.
Chan, T., Narasimhan, C., & Xie, Y. (2007). Impact of treatment effectiveness and side effects on prescription choices. Working paper, Washington University at St. Louis.
Ching, A. (2005). Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. Working paper, University of Toronto.
Coscelli, A., & Shum, M. (2004). An empirical model of learning and patient spillovers in new drug entry. Journal of Econometrics, 122, 213–246. CrossRef
Crawford, G., & Shum, M. (2005). Uncertainty and learning in pharmaceutical demand. Econometrica, 73, 1137–1173. CrossRef
Dai, C., Stafford, R. S., & Alexander, C. G. (2005). National trends in cyclooxygenase-2 inhibitor use since market release: Nonnselective diffusion of a selectively cost-effective innovation. Achieves of Internal Medicine, 165, 171–177.
Dayton, M., & Macready, G. (1988). Concomitant-variable latent class models. Journal of the American Statistical Association, 83, 173–178. CrossRef
DeGroot, M. (1970). Optimal statistical decisions. New York: McGraw-Hill.
Erdem, T., & Keane, M. (1996). Decision-making under uncertainty: Capturing dynamic brand choice processes in turbulent consumer goods market. Marketing Science, 15, 1–20. CrossRef
Food and Drug Administration (2005). Analysis and recommendations for agency action regarding non-steoroidal anti-inflammatory drugs and cardiovascular risk. FDA Memorandum as of April 6, 2005.
Lilien, G. L., Kotler, P., & Moorthy, K. S. (1992). Marketing models. Englewood Cliffs: Prentice Hall.
McFadden, D. (1973). Conditional logit analysis of qualitative choice behavior. In P. Zarembka (Eds.), Frontiers in econometrics. New York: Academic.
Narayanan, S., Manchanda, P., & Chintagunta, P. K. (2005). Temporal differences in the role of marketing communication in new product categories. Journal of Marketing Research, 42, 278–290. CrossRef
Ray, W. A., & Stein, C. M. (2006). Reform of drug regulation beyond an independent drug-safety board. The New England Journal of Medicine, 354, 194–201. CrossRef
Slater, E. E. (2005). Today’s FDA. The New England Journal of Medicine, 352, 293–297. CrossRef
Venkataraman, S., & Stremersch, S. (2007). The debate on influencing doctors’ decisions: Are drug characteristics the missing link? Management Science, 53(11), 1688–1701. CrossRef
- Information, learning, and drug diffusion: The case of Cox-2 inhibitors
Pradeep K. Chintagunta
Ginger Z. Jin
- Springer US
Die Corporate Supply Strategy bei Phoenix Contact GmbH & Co. KG/© [M] michalchm89 | Fotolia